References
- Bhatt SP, Rabe KF, Singh D, Bafadhel M, Vogelmeier CF. A response to therapy for COPD with dupilumab. Lancet Respir Med. 2025;13(1):e3. https://doi.org/10.1016/S2213-2600(24)00371-0 Mathews AM. The functional and psychosocial consequences of COPD. Respir Care. 2023;68(7):914–26. https://doi.org/10.4187/respcare.10542
- Moretta P, Cavallo ND, Candia C, Lanzillo A, Marcuccio G, Santangelo G, Marcuccio L, Ambrosino P, Maniscalco M. Psychiatric disorders in patients with chronic obstructive pulmonary disease: clinical significance and treatment strategies. J Clin Med. 2024;13(21):6418. https://doi.org/10.3390/jcm13216418
- Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, Varghese P. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1–6. https://doi.org/10.1016/j.ejim.2019.12.014
- Volpato E, Martino C, Malerba M, et al. The relationship between anxiety, depression and treatment adherence in COPD: a systematic review. Psychiatry Res. 2021;302:114035.
- Yohannes, A. M., & Alexopoulos, G. S. (2014). Pharmacological Treatment of Depression in Older Patients with Chronic Obstructive Pulmonary Disease: Impact on the Course of the Disease and Health Outcomes. Drugs & Aging, 31(7), 483–492. https://doi.org/10.1007/s40266-014-0186-0
- Alsayed, A. R., Abu-Samak, M. S., & Alkhatib, M. (2023). Asthma-COPD Overlap in Clinical Practice (ACO_CP 2023): Toward Precision Medicine. Journal of Personalized Medicine, 13(4), 677. https://doi.org/10.3390/jpm13040677
- Liu, X., Wang, Y., & Chen, Z. (2024). Cadmium exposure and risk of COPD: a systematic review and meta-analysis. Environmental Research, 235, 117146.
- Loeb, E., Zock, J.-P., Miravitlles, M., Rodríguez, E., Soler-Cataluña, J. J., Soriano, J. B., García-Río, F., De Lucas, P., Alfageme, I., Casanova, C., Rodríguez González-Moro, J. M., Ancochea, J., Cosío, B. G., & Ferrer Sancho, J. (2024). Association between occupational exposure and chronic obstructive pulmonary disease and respiratory symptoms in the Spanish population. Archivos de Bronconeumología, 60(1), 16–22. https://doi.org/10.1016/j.arbres.2023.10.014
- George, J., Ali, S., & Hussain, R. (2024). Credentialed pharmacist-led home medicines reviews targeting treatable traits in COPD. International Journal of Clinical Pharmacy, 46, 625–636.
- Jiang, H., Zhang, X., Zhang, J., Liang, J., & Wang, L. (2024). Association Between Opioid and Benzodiazepine Use and All-Cause Mortality in Individuals with Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease, Volume 19, 2181–2192. https://doi.org/10.2147/copd.s467131
- Global Initiative for Asthma (GINA). 2024 GINA Main Report. Available from: https://ginasthma.org/2024-report/ [Accessed 15 Mar 2025]
- Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: risk factors, prevalence, and future trends. The Lancet, 370, 765–773.
- Popa-Velea, O., & Purcarea, V. (2014). Psychological factors mediating health-related quality of life in COPD. Journal of Medicine and Life, 7, 100–103.
- Sun Y, Fu Z, Bo Q, Mao Z, Ma X, Wang C. The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital. BMC Psychiatry. 2020;20(1):474. https://doi.org/10.1186/s12888-020-02885-6
- Rehman AU, Hassali MAA, Harun SN, Abbas S, Muneswarao J, Hyder Ali IA, Hussain R. Validation and clinical interpretation of the St George’s Respiratory Questionnaire for COPD (SGRQ-C) after adaptation to Malaysian language and culture, in patients with COPD. Health Qual Life Outcomes. 2020;18(1):138. https://doi.org/10.1186/s12955-020-01393-1
- Xiang Y, Luo X. Extrapulmonary comorbidities associated with chronic obstructive pulmonary disease: a review. Int J Chron Obstruct Pulmon Dis. 2024;19:567–578. https://doi.org/10.2147/COPD.S447739